Articles On Probiotec (ASX:PBP)

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is trading flat. More half year earnings results were announced this morning. Here’s a recap and highlight on where things...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The ASX 200 health stocks index (XHJ) rose by 0.60% this morning, compared to the broader index which climbed by 0.40% Biopharmaceutical company Dimerix (ASX:DXB) announced that it has commenced ACTION3, a Phase III study in patients with f...

Wall Street rises again as iron ore rebounds All three US stock market indexes rose last night to their highest levels again. The Dow Jones rose by 0.09%, S&P500 by 0.15%, and tech heavy Nasdaq by 0.52% – all notching record highs. Shar...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Summary The S&P/ASX200 ended lower by just 0.70 points at 7,307.30. The market sentiments were dented as tighter lockdown curbs were imposed in various cities and states. The consumer staple saw a surge in buying as COVID-19 restr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The S&P/ASX200 closed lower Wednesday, dropping 22.40 points or 0.31% to 7270.20 after setting a new 100-day high. Over the last five days, the index has gained 0.73% and is currently 0.88% off of its 52-week high. Sectors ended mixed...

Summary The ASX 200 closed 22.40 points or 0.31% lower at 7,270.20, after setting a new 100-day high. Building products manufacturer Brickworks emerged as the top gainer on the ASX with 11.32% gain. The consumer staples sector emerged...

Aspiring pill-packer Probiotec [ASX:PBP] share price is up 7.18% today, rising on the back of upgraded guidance from management. The post Probiotec Share Price Pop 7% Higher as It Majorly Ups Guidance for FY21 appeared first on Money Mornin...

Aspiring pill-packer Probiotec Ltd [ASX:PBP] share price is up 7.18% today, rising on the back of upgraded guidance from management... The post Probiotec Shares Up As It Majorly Ups Guidance for FY21 (ASX:PBP) appeared first on Money Mornin...

The Probiotec Limited (ASX: PBP) share price is on the move during late afternoon trade. This comes after the pharmaceutical products company provided investors with a trading update and earnings guidance for FY21. At the time of writing,...

Wall Street little changed ahead of inflation data Major indices in the US were little changed last night, ahead of Thursday’s US inflation report for May. The Dow Jones fell by 0.09%, S&P 500 rose by 0.02%, while tech heavy Nasdaq was...

The IDT Australia Limited (ASX: IDT) share price was on fire again on Monday. The pharmaceutical manufacturing company’s shares were up as much as 67% to a multi-year high of 47.5 cents at one stage. When the IDT Australia share price hit...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Local outfit Probiotec Ltd [ASX:PBP] is up 18% at time of writing. Soaring on the back of new takeover talks. And, as a key drug packer and distributor, they may have a lot of work ahead of them in the near future. So this acquisition may b...

Probiotec (ASX: PBP) has made what it calls a “strategic” bid for contract packing business Multipack-LJM – offering to pay an aggregate enterprise value of $52.5 million for the entity. According to Probiotec, Multipack-LJM is one of Austr...

The Probiotec Limited (ASX: PBP) share price is shooting higher as the company presented its annual general meeting. The Probiotec share price is rising despite today’s 1.9% decline in the All Ordinaries Index (ASX: XAO). Shares are curren...

Not all change associated with a pandemic is bad. One thing that could potentially change for the better as a result of COVID-19 is people taking a more proactive approach to their healthcare. The latest pandemic is already prompting people...

Last year, in July, pharmaceuticals company Probiotec (ASX:PBP) announced and completed a $23m acquisition in 31 days. In its half-year report issued today the company said that purchase of contract pharmaceuticals maker ABS was largely beh...

The Probiotec Limited (ASX: PBP) share price continued its impressive run on Wednesday. It shares finished the day almost 7% higher at $2.37. This latest gain means the Probiotec share price is now up a sizeable 55% over the last 12 months...

Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes. The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Trading Places is Stockhead’s weekly recap of substantial holder movements focusing on fund managers. Substantial shareholders are shareholders holding 5 per cent or more of a company’s shares and these can be directors, individual investor...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...